US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
AU612370B2
(en)
*
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
US5965405A
(en)
*
|
1988-04-16 |
1999-10-12 |
Celltech Limited |
Method for producing Fv fragments in eukaryotic cells
|
WO1989009825A1
(en)
*
|
1988-04-16 |
1989-10-19 |
Celltech Limited |
Method for producing recombinant dna proteins
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
EP0768377A1
(de)
|
1988-09-02 |
1997-04-16 |
Protein Engineering Corporation |
Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
|
EP0368684B2
(de)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US7413537B2
(en)
|
1989-09-01 |
2008-08-19 |
Dyax Corp. |
Directed evolution of disulfide-bonded micro-proteins
|
US6458360B1
(en)
|
1990-04-25 |
2002-10-01 |
The Johns Hopkins University |
Soluble complement regulatory molecules
|
US6416971B1
(en)
|
1990-05-15 |
2002-07-09 |
E.R. Squibb & Sons, Inc. |
Soluble single chain T cell receptors
|
GB9012995D0
(en)
*
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
DK1279731T3
(da)
|
1991-03-01 |
2007-09-24 |
Dyax Corp |
Fremgangsmåde til udvikling af bindende miniproteiner
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US5851828A
(en)
*
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US6146850A
(en)
*
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
US5837491A
(en)
*
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
US6025165A
(en)
*
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
SG41929A1
(en)
*
|
1992-09-25 |
1997-08-15 |
Commw Scient Ind Res Org |
Target binding polypeptide
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
US6017697A
(en)
|
1994-11-14 |
2000-01-25 |
Eli Lilly And Company |
Excitatory amino acid receptor protein and related nucleic acid compounds
|
EP1378525A3
(de)
|
1996-06-07 |
2004-01-14 |
Neorx Corporation |
Humanisierte Antikörper die and das gleiche Antigen wie Antikörper NR-LU-13 binden und deren Verwendung in "Pretargeting" Verfahren
|
CA2266339A1
(en)
*
|
1996-09-20 |
1998-03-26 |
The General Hospital Corporation |
Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
|
GB9705376D0
(en)
*
|
1997-03-14 |
1997-04-30 |
Harris William J |
Antibody fragment formulations and assay formats for detecting the presence an d concentration of analytes
|
JP3556459B2
(ja)
|
1998-03-13 |
2004-08-18 |
セイコープレシジョン株式会社 |
Elモジュール
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
TR201809008T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
CA2898314A1
(en)
|
2001-07-19 |
2003-07-31 |
Perian Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
EP1494714A4
(de)
|
2002-04-05 |
2008-03-05 |
Amgen Inc |
Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer
|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
DK1572946T3
(da)
|
2002-09-06 |
2012-07-02 |
Amgen Inc |
Terapeutisk humant monoklonalt anti-IL-1R1-antistof
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
AU2004242614B2
(en)
|
2003-05-30 |
2011-09-22 |
Merus N.V. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1498133A1
(de)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
|
TWI476206B
(zh)
|
2003-07-18 |
2015-03-11 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
PL1842920T5
(pl)
|
2003-09-23 |
2018-04-30 |
University Of North Carolina At Chapel Hill |
Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
|
PT1673450E
(pt)
|
2003-10-14 |
2010-05-11 |
Baxter Int |
Polipéptido de reciclagem de epóxido de vitamina k, vkorc1, um alvo terapêutico de cumarina e seus derivados
|
EP1737971B1
(de)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Gemische bindender proteine
|
CA2562764A1
(en)
|
2004-04-23 |
2005-11-03 |
Richard Kroczek |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
CA2574881C
(en)
|
2004-08-04 |
2013-01-08 |
Amgen Inc. |
Antibodies to dkk-1
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
ZA200705980B
(en)
|
2005-01-07 |
2009-01-28 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
WO2006094735A1
(en)
|
2005-03-11 |
2006-09-14 |
Sanofi-Aventis |
Use of mgc4504
|
AU2005329450A1
(en)
|
2005-03-15 |
2006-09-28 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active Vitamin K-dependent proteins
|
MX2007013609A
(es)
|
2005-05-06 |
2008-01-24 |
Zymogenetics Inc |
Anticuerpos monoclonales de il-31 y meodos de uso.
|
AU2007254715B2
(en)
|
2005-05-06 |
2013-08-29 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
|
WO2006119905A1
(en)
|
2005-05-11 |
2006-11-16 |
Sanofi-Aventis |
Use of a gip promoter polymorphism
|
WO2006124699A2
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
EP2388277A3
(de)
|
2005-07-18 |
2013-03-20 |
Amgen, Inc |
Humane Anti-B7RP1-neutralisierende Antikörper
|
DK1933869T3
(da)
|
2005-09-01 |
2010-03-01 |
Schering Corp |
Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
ES2409835T3
(es)
|
2005-11-28 |
2013-06-28 |
Zymogenetics, Inc. |
Antagonistas de IL-21
|
US20090286962A1
(en)
|
2005-12-20 |
2009-11-19 |
Woolven Benjamin P |
Chimeric antibodies with part new world primate binding regions
|
US7846439B2
(en)
|
2006-02-01 |
2010-12-07 |
Cephalon Australia Pty Ltd |
Domain antibody construct
|
EP2377887A1
(de)
|
2006-03-10 |
2011-10-19 |
Zymogenetics Inc |
IL-17A- und IL-17F-bindende Antikörper und Verfahren zur ihrer Anwendung
|
EA015992B1
(ru)
|
2006-03-17 |
2012-01-30 |
Байоджен Айдек Эмэй Инк. |
Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
|
WO2008014426A2
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
PT2594586E
(pt)
|
2006-09-01 |
2014-11-26 |
Zymogenetics Inc |
Anticorpos monoclonais de il-31 e métodos de utilização
|
KR20090078353A
(ko)
|
2006-11-17 |
2009-07-17 |
노파르티스 아게 |
Lingo 결합 분자 및 그의 제약학적 용도
|
CA2672049C
(en)
|
2006-12-08 |
2016-05-10 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
AU2008219681A1
(en)
|
2007-02-28 |
2008-09-04 |
Merck Sharp & Dohme Corp. |
Combination therapy for treatment of immune disorders
|
ES2465223T3
(es)
|
2007-04-27 |
2014-06-05 |
Zymogenetics, Inc. |
Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
|
WO2008151819A2
(en)
|
2007-06-15 |
2008-12-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
EP2023144A1
(de)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
|
CL2008002444A1
(es)
|
2007-08-21 |
2009-09-04 |
Amgen Inc |
Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
|
EP2615113A3
(de)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8691730B2
(en)
|
2007-09-14 |
2014-04-08 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
ES2667729T3
(es)
|
2007-09-26 |
2018-05-14 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
DK2207808T3
(da)
|
2007-11-02 |
2013-08-05 |
Novartis Ag |
Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
WO2009079212A2
(en)
|
2007-12-03 |
2009-06-25 |
Carnegie Mellon University |
Linked peptide fluorogenic biosensors
|
EP2796466B1
(de)
|
2007-12-07 |
2017-11-22 |
ZymoGenetics, Inc. |
Für IL-31 spezifische humanisierte Antikörpermoleküle
|
EP2105742A1
(de)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Verwendung von Kathepsin-C
|
SI2274008T1
(sl)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
LT2334705T
(lt)
|
2008-09-26 |
2017-03-27 |
Ucb Biopharma Sprl |
Biologiniai produktai
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2219029A1
(de)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
|
HUE027826T2
(en)
|
2009-03-02 |
2016-11-28 |
Aduro Biotech Holdings Europe B V |
Anti-proliferative Ligand Antibodies (APRIL)
|
CN102770457A
(zh)
|
2009-03-10 |
2012-11-07 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
CN103415534A
(zh)
|
2009-03-10 |
2013-11-27 |
贝勒研究院 |
靶向抗原呈递细胞的癌症疫苗
|
BRPI1009455A2
(pt)
|
2009-03-10 |
2016-03-01 |
Baylor Res Inst |
anticorpos anti-c40 e usos dos mesmos
|
CA2889453C
(en)
|
2009-03-20 |
2018-11-06 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2010249470B2
(en)
|
2009-05-20 |
2015-06-25 |
Novimmune S.A. |
Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
|
CN102762593B
(zh)
|
2009-07-31 |
2015-05-20 |
梅达雷克斯有限责任公司 |
抗btla的完全人抗体
|
EP2293072A1
(de)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Verwendung von Kathepsin H
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
WO2011055550A1
(ja)
|
2009-11-05 |
2011-05-12 |
国立大学法人大阪大学 |
自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
|
AU2010321832B2
(en)
|
2009-11-20 |
2014-08-14 |
Amgen Inc. |
Anti-Orai1 antigen binding proteins and uses thereof
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
WO2011150079A1
(en)
|
2010-05-25 |
2011-12-01 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
KR101847572B1
(ko)
|
2010-05-28 |
2018-05-24 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
신혈관신생에 기초한 안 질환 치료용 항-cd160 특이적 항체
|
JP6023706B2
(ja)
|
2010-07-09 |
2016-11-09 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
Cd27に対するアゴニスト抗体
|
EP2593594B1
(de)
|
2010-07-16 |
2017-09-27 |
Adimab, LLC |
Antikörperbibliotheken
|
CA2807673A1
(en)
|
2010-08-10 |
2012-02-16 |
Xinyi Cynthia Chen |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
KR20130110169A
(ko)
|
2010-09-22 |
2013-10-08 |
암젠 인크 |
담체 면역글로뷸린 및 이것의 용도
|
WO2012058393A2
(en)
|
2010-10-27 |
2012-05-03 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
TW202323302A
(zh)
|
2010-11-30 |
2023-06-16 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
UY33807A
(es)
|
2010-12-17 |
2012-07-31 |
Sanofi Sa |
miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
EP2655607A4
(de)
|
2010-12-21 |
2014-05-14 |
Univ North Carolina |
Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
KR20140145947A
(ko)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Nav1.3과 nav1.7의 유효한 선별적 저해제
|
EP2688592A4
(de)
|
2011-03-25 |
2015-07-22 |
Baylor Res Inst |
Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
|
PE20140964A1
(es)
|
2011-03-30 |
2014-08-17 |
Boehringer Ingelheim Int |
Antidotos anticoagulantes
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
KR101338517B1
(ko)
|
2011-04-18 |
2013-12-10 |
연세대학교 산학협력단 |
인간 간-카르복실에스터라제 1을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
|
EP2518157A1
(de)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
EP2537532A1
(de)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
|
EP2734546A1
(de)
|
2011-07-18 |
2014-05-28 |
Amgen Inc. |
Apelinantigen-bindende proteine und verwendungen davon
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトlcat抗原結合タンパク質および治療法におけるそれらの使用
|
WO2013119419A1
(en)
|
2012-02-08 |
2013-08-15 |
North Carolina State University |
Treatment of allergic diseases with recombinant antibodies
|
EA035344B1
(ru)
|
2012-04-20 |
2020-05-29 |
Мерюс Н.В. |
Способ получения двух антител из одной клетки-хозяина
|
JP6370774B2
(ja)
|
2012-04-27 |
2018-08-08 |
ノヴォ ノルディスク アー/エス |
ヒトcd30リガンド抗原結合性タンパク質
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
BR112014031028A2
(pt)
|
2012-06-11 |
2017-08-15 |
Amgen Inc |
Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
HUE041499T2
(hu)
|
2012-11-21 |
2019-05-28 |
Janssen Biotech Inc |
Bispecifikus EGFR/C-MET-ellenanyagok
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JP6466904B2
(ja)
|
2013-03-15 |
2019-02-06 |
ヤンセン バイオテツク,インコーポレーテツド |
インターフェロンアルファ及びオメガ抗体アンタゴニスト
|
EP3683237A1
(de)
|
2013-03-15 |
2020-07-22 |
Amgen Inc. |
Humane pac1-antikörper
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ccr7抗原結合タンパク質に関係する方法および組成物
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
EP3013422A1
(de)
|
2013-06-28 |
2016-05-04 |
Amgen Inc. |
Verfahren zur behandlung von homozygoter familiärer hypercholesterolämie
|
EP3027210A1
(de)
|
2013-08-02 |
2016-06-08 |
Aduro Biotech Holdings, Europe B.V. |
Kombination von cd27-agonisten und immun-checkpoint-hemmung zur immunstimulation
|
JP6599861B2
(ja)
|
2013-08-07 |
2019-10-30 |
リグスホスピタレット コペンハーゲン ユニバーシティ ホスピタル |
男性不妊治療用の抗体、化合物、およびその誘導体
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
AU2014317009A1
(en)
|
2013-09-05 |
2016-03-10 |
Aduro Biotech Holdings, Europe B.V. |
CD70-binding peptides and method, process and use relating thereto
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
WO2015069865A1
(en)
|
2013-11-06 |
2015-05-14 |
Janssen Biotech, Inc. |
Anti-ccl17 antibodies
|
CN106029697B
(zh)
|
2013-12-20 |
2021-06-04 |
英特维特国际股份有限公司 |
具有经修饰的ch2-ch3序列的犬抗体
|
CN106062005A
(zh)
|
2013-12-30 |
2016-10-26 |
医药生命融合研究团 |
抗krs单克隆抗体及其用途
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
EP3992210A1
(de)
|
2014-01-13 |
2022-05-04 |
Baylor Research Institute |
Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
AU2015305754B2
(en)
|
2014-08-19 |
2018-10-25 |
Merck Sharp & Dohme Llc |
Anti-tigit antibodies
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
CN108064182B
(zh)
|
2014-09-09 |
2021-09-03 |
詹森生物科技公司 |
采用抗cd38抗体的联合疗法
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
AU2015355731B2
(en)
|
2014-12-03 |
2018-07-26 |
Aimed Bio Inc. |
Antibody binding to neuropilin 1 and use thereof
|
WO2016100615A2
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Chicago |
Methods and composition for neutralization of influenza
|
EP3916017A1
(de)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1-antikörper
|
EP3085709B1
(de)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanisierte antikörper gegen menschliches rankl, pharmazeutische zusammensetzung und verwendung davon
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
DK3244911T3
(da)
|
2015-01-12 |
2019-12-16 |
Rigshospitalet Copenhagen Univ Hospital |
Fremgangsmåde til bestemmelse af en sandsynlig virkning af en behandling til forbedring af mandlig ufrugtbarhed
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
CA2978450A1
(en)
|
2015-03-04 |
2016-09-09 |
The University Of Chicago |
Beta-catenin inhibitors in cancer immunotherapy
|
BR112017020915A2
(pt)
|
2015-04-02 |
2018-07-10 |
Intervet Int Bv |
?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
|
EP4219561A3
(de)
|
2015-05-20 |
2023-11-08 |
Janssen Biotech, Inc. |
Anti-cd38-antikörper zur behandlung von leichtkettiger amyloidose und anderen cd38-positiven hämatologischen malignomen
|
RU2017141448A
(ru)
|
2015-06-01 |
2019-07-15 |
Зэ Юниверсити Оф Чикаго |
Лечение рака путем манипуляций с комменсальной микрофлорой
|
EP3310386B1
(de)
|
2015-06-22 |
2021-07-21 |
Janssen Biotech, Inc. |
Kombinationstherapien für blutmalignome mit anti-cd38-antikörpern survivin-inhibitoren
|
FI3313441T3
(fi)
|
2015-06-24 |
2024-03-28 |
Janssen Biotech Inc |
Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
EP3331563B1
(de)
|
2015-08-05 |
2023-04-19 |
Janssen Biotech, Inc. |
Anti-cd154-antikörper und verfahren zur verwendung davon
|
MA43053A
(fr)
|
2015-09-30 |
2018-08-08 |
Janssen Biotech Inc |
Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
MA43187B1
(fr)
|
2015-11-03 |
2021-02-26 |
Janssen Biotech Inc |
Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
|
CR20180234A
(es)
|
2015-11-03 |
2018-09-11 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3378487B1
(de)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Kombinationstherapie mit t-zell-neuausrichtendem antigenbindendem molekül gegen zelle mit immunsuppressiver funktion
|
KR101896882B1
(ko)
|
2015-11-30 |
2018-09-11 |
앱클론(주) |
Vegfr2에 특이적으로 결합하는 항체
|
WO2017106129A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Anti-lag3 antibodies and antigen-binding fragments
|
JP2019502698A
(ja)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク,インコーポレーテツド |
Hla−drに特異的に結合する抗体及びその使用
|
UA127495C2
(uk)
|
2015-12-23 |
2023-09-13 |
Амджен Інк. |
Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
|
US20170198290A1
(en)
|
2016-01-08 |
2017-07-13 |
Northwestern University |
Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
|
ES2823173T3
(es)
|
2016-01-27 |
2021-05-06 |
Just Biotherapeutics Inc |
Promotor híbrido y usos del mismo
|
KR20240118898A
(ko)
|
2016-02-03 |
2024-08-05 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
CN109476738A
(zh)
|
2016-02-15 |
2019-03-15 |
社会福祉法人三星生命公益财团 |
抗EGFRvIII的抗体及其用途
|
US11072666B2
(en)
|
2016-03-14 |
2021-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CN117903307A
(zh)
|
2016-04-01 |
2024-04-19 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
SG11201808622SA
(en)
|
2016-04-01 |
2018-10-30 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
EP3984559A1
(de)
|
2016-04-01 |
2022-04-20 |
Kite Pharma, Inc. |
Chimäre antigen- und t-zell-rezeptoren und ihre anwendungsverfahren
|
RS63735B1
(sr)
|
2016-04-01 |
2022-12-30 |
Kite Pharma Inc |
Himerni receptori i postupci njihove upotrebe
|
EP3445393A4
(de)
|
2016-04-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Cmv-neutralisierende antigenbindende proteine
|
KR20220103806A
(ko)
|
2016-05-18 |
2022-07-22 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료용 항-pd1 및 항-lag3 항체
|
BR112018074275A2
(pt)
|
2016-05-27 |
2019-10-01 |
Orum Therapeutics Inc |
anticorpo de penetração no citosol e método de produção do mesmo
|
SG11201810779PA
(en)
|
2016-06-03 |
2019-01-30 |
Samsung Life Public Welfare Foundation |
Method for screening antibody using patient-derived tumor spheroids
|
WO2017209554A2
(ko)
|
2016-06-03 |
2017-12-07 |
사회복지법인 삼성생명공익재단 |
항-nrp1 항체 스크리닝 방법
|
WO2017209553A2
(ko)
|
2016-06-03 |
2017-12-07 |
사회복지법인 삼성생명공익재단 |
환자 유래 세포를 이용한 항체 스크리닝 방법
|
CA3026238C
(en)
|
2016-06-03 |
2023-07-25 |
Samsung Life Public Welfare Foundation |
Anti-nrp1 antibody screening method
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
CD38に特異的に結合する抗体によるIgE媒介疾患の治療
|
EP3487506A1
(de)
|
2016-07-20 |
2019-05-29 |
Hybrigenics SA |
Kombinationen von inecalcitol mit einem anti-cd38-mittel und deren verwendungen zur behandlung von krebs
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
BR112019002258A2
(pt)
|
2016-08-05 |
2019-05-14 |
Y-Biologics Inc. |
anticorpo que se liga a pd-1 ou fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenir ou tratar câncer
|
WO2018026249A1
(ko)
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
|
JP6925421B2
(ja)
|
2016-08-05 |
2021-08-25 |
ワイ−バイオロジクス・インコーポレイテッド |
プログラム化された細胞死蛋白質リガンド−1(pd−l1)に対する抗体及びその用途
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
EP3515503A4
(de)
|
2016-09-23 |
2020-09-23 |
The Regents Of The University Of Michigan |
Manipulierte lymphozyten
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3523330A1
(de)
|
2016-10-04 |
2019-08-14 |
Fairbanks Pharmaceuticals, Inc. |
Anti-fstl3-antikörper und verwendungen davon
|
ES2908239T3
(es)
|
2016-10-28 |
2022-04-28 |
Astute Medical Inc |
Uso de anticuerpos contra timp-2 para la mejora de la función renal
|
EP3538558A4
(de)
|
2016-11-09 |
2020-07-15 |
North Carolina State University |
Behandlung allergischer erkrankungen mit einem chimären protein
|
US11135266B2
(en)
|
2016-11-21 |
2021-10-05 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations and uses thereof
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
US11111292B2
(en)
|
2016-12-23 |
2021-09-07 |
Cephalon, Inc. |
Anti-IL-5 antibodies
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018148489A1
(en)
|
2017-02-09 |
2018-08-16 |
Promega Corporation |
Analyte detection immunoassay
|
CN110636861B
(zh)
|
2017-03-03 |
2022-07-08 |
詹森生物科技公司 |
用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
|
KR20240135066A
(ko)
|
2017-04-13 |
2024-09-10 |
사이로파 비.브이. |
항-sirp 알파 항체
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
RU2751720C2
(ru)
|
2017-05-30 |
2021-07-16 |
Чонг Кун Данг Фармасьютикал Корп. |
Новое анти-с-мет антитело и его применение
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
JP2020522266A
(ja)
|
2017-06-05 |
2020-07-30 |
ヤンセン バイオテツク,インコーポレーテツド |
非対称なch2−ch3領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
|
WO2018226690A1
(en)
|
2017-06-05 |
2018-12-13 |
The University Of Chicago |
Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
|
KR102692379B1
(ko)
|
2017-06-05 |
2024-08-05 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 사용 방법
|
PE20200013A1
(es)
|
2017-06-20 |
2020-01-06 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
JP7250706B2
(ja)
|
2017-06-21 |
2023-04-03 |
アムジエン・インコーポレーテツド |
胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
|
EP3661562B1
(de)
|
2017-08-04 |
2024-10-02 |
Amgen Inc. |
Verfahren zur konjugation von cys-mabs
|
EP3672611A4
(de)
|
2017-08-25 |
2021-07-14 |
Janssen Biotech, Inc. |
Fcyrii-bindende fibronectin-typ-iii-domänen, deren konjugate und diese enthaltende multispezifische moleküle
|
CN114533863A
(zh)
|
2017-09-15 |
2022-05-27 |
凯德药业股份有限公司 |
用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
CA3076630A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
JP7260553B2
(ja)
|
2017-10-06 |
2023-04-18 |
ザ・ユニバーシティ・オブ・シカゴ |
がん特異的抗原に対するtリンパ球のスクリーニング
|
CN112105380A
(zh)
|
2017-10-11 |
2020-12-18 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体和其用途
|
SG11202003585VA
(en)
|
2017-10-20 |
2020-05-28 |
Pharmabcine Inc |
Anti-vista antibody and use thereof
|
CA3079242A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
CN111356471A
(zh)
|
2017-11-20 |
2020-06-30 |
济世发展生物药业有限公司 |
包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
|
AU2018383679A1
(en)
|
2017-12-11 |
2020-05-07 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
KR102311838B1
(ko)
|
2017-12-27 |
2021-10-14 |
주식회사 파멥신 |
항-pd-l1 항체 및 이의 용도
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
WO2019147822A2
(en)
|
2018-01-24 |
2019-08-01 |
Northwestern University |
Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
WO2019169231A1
(en)
|
2018-03-02 |
2019-09-06 |
The University Of Chicago |
Methods and composition for neutralization of influenza
|
KR102275930B1
(ko)
|
2018-03-14 |
2021-07-12 |
(주)알테오젠 |
Folr1에 특이적으로 결합하는 항체 및 그의 용도
|
EP3768281B1
(de)
|
2018-03-19 |
2023-07-05 |
The Regents Of The University Of Michigan |
Zusammensetzungen und verfahren zur aktivierung von t-zellen und zytokinen
|
WO2019183437A1
(en)
|
2018-03-23 |
2019-09-26 |
North Carolina State University |
Methods and compositions for antibody to high affinity receptor for ige
|
UY38182A
(es)
|
2018-04-10 |
2019-10-31 |
Amgen Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
WO2019206095A1
(zh)
|
2018-04-24 |
2019-10-31 |
安源医药科技(上海)有限公司 |
针对tim-3的抗体及其用途
|
EP3798305A4
(de)
|
2018-04-27 |
2022-02-09 |
Aimed Bio Inc. |
Magnetbasiertes biopanningverfahren durch anbringen eines magnetischen kügelchens an einer zelle
|
EP3790904A1
(de)
|
2018-05-08 |
2021-03-17 |
Amgen Inc. |
Bispezifische antikörper mit spaltbaren c-terminalen ladungsgepaarten tags
|
KR20210011002A
(ko)
|
2018-05-16 |
2021-01-29 |
얀센 바이오테크 인코포레이티드 |
암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
AU2019274652A1
(en)
|
2018-05-24 |
2020-11-26 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-TMEFF2 antibodies and there uses
|
PE20210132A1
(es)
|
2018-05-24 |
2021-01-19 |
Janssen Biotech Inc |
Anticuerpos anti-cd3 y usos de estos
|
EA202092839A1
(ru)
|
2018-05-24 |
2021-02-12 |
Янссен Байотек, Инк. |
Агенты, связывающиеся с psma, и виды их применения
|
KR102115300B1
(ko)
|
2018-06-01 |
2020-05-26 |
재단법인 목암생명과학연구소 |
항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
KR102250234B1
(ko)
|
2018-06-29 |
2021-05-10 |
주식회사 와이바이오로직스 |
Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
|
CN112771080B
(zh)
|
2018-07-18 |
2024-07-19 |
美国安进公司 |
针对steap1的嵌合受体及其使用方法
|
AU2019312576A1
(en)
|
2018-08-01 |
2021-02-25 |
Cephalon, LLC |
Anti-CXCR2 antibodies and uses thereof
|
CA3106829A1
(en)
|
2018-08-03 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
EP3835320A4
(de)
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
Chimärer antigenrezeptor, der an hla-dr bindet, und car-t-zelle
|
EP3836954A1
(de)
|
2018-08-13 |
2021-06-23 |
Iltoo Pharma |
Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
|
HRP20240821T1
(hr)
|
2018-08-27 |
2024-09-27 |
Affimed Gmbh |
Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
|
KR20210061341A
(ko)
|
2018-09-13 |
2021-05-27 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
신규한 lilrb4 항체 및 이의 용도
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
CA3116878A1
(en)
|
2018-10-17 |
2020-04-23 |
Janssen Biotech, Inc. |
Method of providing subcutaneous administration of anti-cd38 antibodies
|
WO2020088164A1
(zh)
|
2018-11-01 |
2020-05-07 |
山东新时代药业有限公司 |
双特异性抗体及其用途
|
CN113015805A
(zh)
|
2018-11-13 |
2021-06-22 |
詹森生物科技公司 |
抗cd38抗体产生期间的痕量金属的控制
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
EP3887830A2
(de)
|
2018-11-28 |
2021-10-06 |
Promega Corporation |
Reaktive peptidmarkierung
|
EP3904385A4
(de)
|
2018-12-27 |
2023-04-19 |
Akeso Biopharma, Inc. |
Antikörper gegen humanes il-4ra und verwendung davon
|
CN113573729A
(zh)
|
2019-01-10 |
2021-10-29 |
詹森生物科技公司 |
前列腺新抗原及其用途
|
AU2020216295A1
(en)
|
2019-01-28 |
2021-09-09 |
Maple Biotech Llc |
PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
EP3920975A4
(de)
|
2019-02-06 |
2022-09-21 |
The Regents of The University of Michigan |
Chimäre, auf abnormale glykobiologie abzielende antigenrezeptoren
|
CA3129317A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
WO2020168315A1
(en)
|
2019-02-15 |
2020-08-20 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
CN113767113A
(zh)
|
2019-02-15 |
2021-12-07 |
因特格尔莫来库乐有限公司 |
密封蛋白6抗体及其用途
|
EP3930687A4
(de)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
Verfahren und zusammensetzungen zur behandlung von entzündungs- und autoimmunzuständen mit ecm-affinitätspeptiden, die mit entzündungshemmenden mitteln verbunden sind
|
WO2020174370A2
(en)
|
2019-02-26 |
2020-09-03 |
Janssen Biotech, Inc. |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
WO2020180121A1
(ko)
|
2019-03-06 |
2020-09-10 |
주식회사 레고켐 바이오사이언스 |
인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
US11541086B2
(en)
|
2019-03-14 |
2023-01-03 |
Northwestern Univeristy |
Compositions and methods for treating Alzheimer's disease
|
JP2022526907A
(ja)
|
2019-03-20 |
2022-05-27 |
プロメガ コーポレイション |
光親和性プローブ
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
TW202104266A
(zh)
|
2019-04-19 |
2021-02-01 |
美商健生生物科技公司 |
使用抗psma/cd3抗體來治療腎癌之方法
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
WO2020230091A1
(en)
|
2019-05-14 |
2020-11-19 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
|
AU2020286523A1
(en)
|
2019-06-03 |
2022-02-03 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
EP4023230A4
(de)
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörper-spaltungsstellenbindendes molekül
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
CA3143680A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
MA56533A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
|
CA3140208A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
CN113950485A
(zh)
|
2019-07-10 |
2022-01-18 |
中外制药株式会社 |
密蛋白-6结合分子及其用途
|
BR112022000721A2
(pt)
|
2019-07-15 |
2022-03-08 |
Intervet Int Bv |
Anticorpos caninizados contra ctla-4 canina
|
WO2021018114A1
(zh)
|
2019-07-30 |
2021-02-04 |
中山康方生物医药有限公司 |
抗人p40蛋白域抗体及其用途
|
US20220324971A1
(en)
|
2019-09-03 |
2022-10-13 |
Akeso Biopharma, Inc |
Anti-cd47 monoclonal antibody and use thereof
|
KR20220088847A
(ko)
|
2019-09-04 |
2022-06-28 |
주식회사 와이바이오로직스 |
항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
MX2022005595A
(es)
|
2019-11-07 |
2022-08-10 |
Amgen Inc |
Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
EP4065699A1
(de)
|
2019-11-27 |
2022-10-05 |
Promega Corporation |
Mehrteilige luciferase-peptide und polypeptide
|
BR112022010680A2
(pt)
|
2019-12-03 |
2022-08-16 |
Evotec Int Gmbh |
Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
|
EP4069290A1
(de)
|
2019-12-03 |
2022-10-12 |
Evotec International GmbH |
Interferon-assoziierte antigenbindende proteine zur verwendung bei der behandlung von hepatitis-b-infektionen
|
WO2021119149A1
(en)
|
2019-12-10 |
2021-06-17 |
Promega Corporation |
Compositions and methods for bioluminescent detection using multifunctional probes
|
TW202130350A
(zh)
|
2019-12-17 |
2021-08-16 |
美商奇努克治療美國公司 |
用阿曲生坦(ATRASENTAN)治療IgA腎病的方法
|
JP2023508366A
(ja)
|
2019-12-27 |
2023-03-02 |
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク |
二重特異性fcyriii×cd30抗体構築体の製造方法
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
BR112022017526A2
(pt)
|
2020-03-31 |
2022-10-18 |
Chugai Pharmaceutical Co Ltd |
Método para produzir moléculas de ligação de antígeno multiespecíficas
|
JPWO2021201202A1
(de)
|
2020-04-02 |
2021-10-07 |
|
|
US20230183354A1
(en)
|
2020-04-30 |
2023-06-15 |
Sairopa B.V. |
Anti-cd103 antibodies
|
BR112022022800A2
(pt)
|
2020-05-11 |
2022-12-13 |
Janssen Biotech Inc |
Métodos para tratamento de mieloma múltiplo
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
WO2021234560A1
(en)
|
2020-05-19 |
2021-11-25 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
IL300225A
(en)
|
2020-07-31 |
2023-03-01 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition including chimeric receptor expressing cells
|
CN116669763A
(zh)
|
2020-09-14 |
2023-08-29 |
詹森药业有限公司 |
Fgfr抑制剂联合疗法
|
IL301361A
(en)
|
2020-09-16 |
2023-05-01 |
Janssen Biotech Inc |
Treatment methods for multiple myeloma
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
CN116829586A
(zh)
|
2020-10-21 |
2023-09-29 |
勃林格殷格翰国际有限公司 |
用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
|
JP2023549116A
(ja)
|
2020-11-06 |
2023-11-22 |
アムジエン・インコーポレーテツド |
選択性が増大した多標的二重特異性抗原結合分子
|
WO2022178090A2
(en)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Dnase fusion polypeptides and related compositions and methods
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
AU2022233518A1
(en)
|
2021-03-09 |
2023-10-26 |
Janssen Biotech, Inc. |
Treatment of cancers lacking egfr-activating mutations
|
MX2023011690A
(es)
|
2021-04-02 |
2023-12-15 |
Amgen Inc |
Construcciones de unión a mageb2.
|
CA3193664A1
(en)
|
2021-04-14 |
2022-10-20 |
Akeso Biopharma, Inc. |
Anti-cd47 monoclonal antibody and use thereof
|
TW202308689A
(zh)
|
2021-04-21 |
2023-03-01 |
美商健生生物科技公司 |
高濃度的雙特異性抗體調配物
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
AU2022278013A1
(en)
|
2021-05-18 |
2024-01-18 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
|
CA3218786A1
(en)
|
2021-05-25 |
2022-12-01 |
Lifei HOU |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
CN117999085A
(zh)
|
2021-06-09 |
2024-05-07 |
埃沃特克国际有限责任公司 |
用于治疗或预防冠状病毒感染的干扰素相关的抗原结合蛋白
|
EP4355778A1
(de)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Neue trispezifische bindungsmoleküle
|
CN115558023A
(zh)
|
2021-07-02 |
2023-01-03 |
安源医药科技(上海)有限公司 |
抗cd3抗体及其用途
|
WO2023287707A1
(en)
|
2021-07-15 |
2023-01-19 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
WO2023015169A1
(en)
|
2021-08-02 |
2023-02-09 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
WO2023015170A2
(en)
|
2021-08-02 |
2023-02-09 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
EP4419556A1
(de)
|
2021-10-18 |
2024-08-28 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Anti-egfr-antikörper, anti-cmet-antikörper, anti-vegf-antikörper, multispezifische antikörper und verwendungen davon
|
AU2022377061A1
(en)
|
2021-10-29 |
2024-05-16 |
Zielbio, Inc. |
Cancer specific plectin-1 specific antibodies and methods of use thereof
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
US20230136301A1
(en)
|
2021-11-03 |
2023-05-04 |
Janssen Biotech, Inc. |
Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
|
AU2022380722A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
KR20240103014A
(ko)
|
2021-11-09 |
2024-07-03 |
암젠 인크 |
항체 펩티드 접합체 생성 방법
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
EP4448550A2
(de)
|
2021-12-15 |
2024-10-23 |
Interius Biotherapeutics, Inc. |
Pseudotypisierte virale partikel, zusammensetzungen damit und verwendungen davon
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法
|
US20230357266A1
(en)
|
2022-05-04 |
2023-11-09 |
Promega Corporation |
Photoactivatable compounds and uses thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US11723955B1
(en)
|
2022-05-13 |
2023-08-15 |
Allgenesis Biotherapeutics Inc. |
VEGFR fusion protein pharmaceutical composition
|
US20240076343A1
(en)
|
2022-06-16 |
2024-03-07 |
Cephalon Llc |
Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
|
WO2024003837A1
(en)
|
2022-06-30 |
2024-01-04 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024079711A1
(en)
|
2022-10-14 |
2024-04-18 |
Janssen Research & Development, Llc |
Method for detection of antibody-dependent cellular phagocytosis
|
WO2024084463A1
(en)
|
2022-10-21 |
2024-04-25 |
Janssen Research & Development, Llc |
Methods and systems for microbial detection using infrared spectroscopy
|
WO2024084460A1
(en)
|
2022-10-21 |
2024-04-25 |
Janssen Research & Development, Llc |
Methods for microbial detection
|
WO2024084461A1
(en)
|
2022-10-21 |
2024-04-25 |
Janssen Research & Development, Llc |
Methods and systems for microbial detection using raman spectroscopy
|
WO2024092240A1
(en)
|
2022-10-28 |
2024-05-02 |
Chinook Therapeutics, Inc. |
Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
|
WO2024095173A1
(en)
|
2022-11-02 |
2024-05-10 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
US12110344B2
(en)
|
2022-11-21 |
2024-10-08 |
Dianthus Therapeutics Opco, Inc. |
Antibodies that bind to cis and uses thereof
|
WO2024118771A1
(en)
|
2022-11-30 |
2024-06-06 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
WO2024126293A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
|
WO2024126289A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
|
WO2024126294A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
|
WO2024151213A2
(en)
|
2023-01-12 |
2024-07-18 |
National University Of Singapore |
Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies
|
WO2024170486A1
(en)
|
2023-02-13 |
2024-08-22 |
Intervet International B.V. |
Canine antibodies to canine il-4
|
WO2024170485A1
(en)
|
2023-02-13 |
2024-08-22 |
Intervet International B.V. |
Canine antibodies to canine il-13
|
WO2024180469A1
(en)
|
2023-02-28 |
2024-09-06 |
Janssen Biotech, Inc. |
Compositions comprising a bispecific gprc5d/cd3 antibody
|
WO2024187062A1
(en)
|
2023-03-08 |
2024-09-12 |
Amgen Inc. |
Controlled-ice nucleation lyophilization process for bispecific molecules
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|